New drug SLC-3010 takes on advanced solid tumors

NCT ID NCT05525247

Terminated Disease control Sponsor: Selecxine Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This trial studies a new drug called SLC-3010, given alone or with chemotherapy (gemcitabine), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find safe doses and see if the drug can shrink tumors. The study is in two parts: first, finding the right dose, then testing that dose in more patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SLC-3010
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is an early-phase trial with a small number of participants. The drug may not shrink tumors or could cause side effects. Success in this phase does not guarantee later approval.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Selecxine Investigator site

Sarasota, Florida, 34232, United States
Selecxine Investigator site

Detroit, Michigan, 48201, United States
Selecxine Investigator site

Oklahoma City, Oklahoma, 73104, United States
Selecxine Investigator site

Waratah, New South Wales, 2298, Australia
Selecxine Investigator site

Brentwood, Perth, 6153, Australia
Selecxine Investigator site

Seoul, Jongno-gu, 03080, South Korea
Selecxine Investigator site

Seoul, Seodaemun-gu, 03722, South Korea
Selecxine Investigator site

Gyeonggi-do, Seongnam-si, 13620, South Korea
Selecxine Investigator site

Seoul, Songpa-gu, 05505, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.